Improving the Clinical
and Economic Burden of Ankylosing Spondylitis: Targeting IL17/IL-23
Pathways for Optimized Patient Outcomes
A continuing medical
education activity sponsored by NAMCP and AAMCN
This webinar series will provide critical updates on the advances in
the management of AS, including
how to translate the most recent data into clinical and
These are archives of live webinars held between February 21 to
February 28, 2020.
If you participated in any of the live webinars, you are not
claim credit from the archive of that webinar.
By clicking on each of the titles, you will be able to participate
in each part.
It is not required that you participate in all 3 or in order.
Each session has its own specific valid dates
This series is supported by educational
Lilly and Novartis Pharmaceuticals Corporation
This activity is intended for healthcare professionals practicing in managed
Instructions for CME/CNE: Complete the pre-test,
listen to the audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your internet
browser without completing the post test, you will have ONE more opportunity to
complete. A score of 70% must be achieved on the post test to receive continuing
education credits. If you do not pass the post test after two attempts, you will
not be eligible to try again. Once you complete the evaluation form and score
70% or higher on your post test, you will automatically be given your
Ankylosing spondylitis (AS) is an immune-mediated
chronic inflammatory disease that typically affects the sacroiliac (SI) joints.
Patients with AS suffer from debilitating pain and joint fusion that severely
limits their mobility and functional capacity. It is estimated that AS affects
approximately 1.6 million people in the US. Due to an aging population,
declining number of rheumatologists, and limited access to care, care for
patients with AS is suboptimal and costly. Fortunately for patients with this
disease, recent advances in pathogenesis have led to an increased understanding
of the disease, which has subsequently led to the development of novel targeted
agents shown to slow its progression, including options targeting IL-17/IL-23
This webinar series on integrating IL-17 and IL-23 therapies into the treatment
paradigm will provide attendees with updated education on these novel treatment
options, emerging value equations, the limitations of established treatment
options, and recent clinical data on these new agents to optimize the management
of patients with AS.